Abstract
New drugs are desperately needed to combat XDR-TB as effective treatment involves at least four drugs to which the patient is sensitive or has never received in the past. Most Indian patients have received almost all second line drugs and have amplified resistance to most of the available drugs. Thioridazine has proven anti tuberculous effects in vitro and in vivo mouse models and we used this drug as salvage therapy in 4 Indian patients with XDR (near total drug resistance) with advanced disease. We found this drug to be well tolerated, even in this malnourished and ill patient population. It also resulted in clinical improvement in 3 of the 4 patients. Larger studies are being planned with this drug being added on to standardized or individualized XDR-TB regimens at an earlier stage. Because thioridazine has been used successfully for therapy of XDR-TB when in combination with antibiotics to which the patients were nonresponsive, the suggestion has been made that Thioridazine is eligible for patent as “New Use”.
Keywords: Thioridazine, salvage drug, XDR-TB, QT-interval, TB Strains, sputum conversion, central inflammatory response, antituberculous effects, drug resistant tuberculosis, thioridazine therapy
Recent Patents on Anti-Infective Drug Discovery
Title: Safety and Efficacy of Thioridazine as Salvage Therapy in Indian Patients with XDR-TB
Volume: 6 Issue: 2
Author(s): Zarir F. Udwadia, Tiyas Sen and Lancelot M. Pinto
Affiliation:
Keywords: Thioridazine, salvage drug, XDR-TB, QT-interval, TB Strains, sputum conversion, central inflammatory response, antituberculous effects, drug resistant tuberculosis, thioridazine therapy
Abstract: New drugs are desperately needed to combat XDR-TB as effective treatment involves at least four drugs to which the patient is sensitive or has never received in the past. Most Indian patients have received almost all second line drugs and have amplified resistance to most of the available drugs. Thioridazine has proven anti tuberculous effects in vitro and in vivo mouse models and we used this drug as salvage therapy in 4 Indian patients with XDR (near total drug resistance) with advanced disease. We found this drug to be well tolerated, even in this malnourished and ill patient population. It also resulted in clinical improvement in 3 of the 4 patients. Larger studies are being planned with this drug being added on to standardized or individualized XDR-TB regimens at an earlier stage. Because thioridazine has been used successfully for therapy of XDR-TB when in combination with antibiotics to which the patients were nonresponsive, the suggestion has been made that Thioridazine is eligible for patent as “New Use”.
Export Options
About this article
Cite this article as:
F. Udwadia Zarir, Sen Tiyas and M. Pinto Lancelot, Safety and Efficacy of Thioridazine as Salvage Therapy in Indian Patients with XDR-TB, Recent Patents on Anti-Infective Drug Discovery 2011; 6 (2) . https://dx.doi.org/10.2174/157489111796064614
DOI https://dx.doi.org/10.2174/157489111796064614 |
Print ISSN 1574-891X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4071 |
Related Articles
-
It’s Time for An Epigenomics Roadmap of Heart Failure
Current Genomics Recently Patented and Widely Used Valves for Transcatheter Aortic Valve Implantation
Recent Patents on Cardiovascular Drug Discovery Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today:Glucagon-Like Peptide-1 (GLP-1) and Glucose-ependent Insulinotropic Polypeptide (GIP)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) B-Type Natriuretic Peptide: Endogenous Regulator of Myocardial Structure, Biomarker and Therapeutic Target
Current Molecular Medicine Selectivity Problems with Drugs Acting on Cardiac Na<sup>+</sup> and Ca<sup>2+</sup> Channels
Current Medicinal Chemistry The Role of Molecular Imaging in the Assessment of Cardiac Amyloidosis: State-of-the-Art
Current Radiopharmaceuticals Flow Cytometric Analysis of Protein Aggregates
Protein & Peptide Letters Clinical Pharmacokinetics of Systemically Administered Antimycotics
Current Clinical Pharmacology ACE Inhibition Prevents Diastolic Ca2+ Overload and Loss of Myofilament Ca2+ Sensitivity after Myocardial Infarction
Current Molecular Medicine Trypanocidal Activity of Nitroaromatic Prodrugs: Current Treatments and Future Perspectives
Current Topics in Medicinal Chemistry Sarcolemmal K<sub>ATP</sub> Channel Modulators and Cardiac Arrhythmias
Current Medicinal Chemistry The Multi-modality Cardiac Imaging Approach to Cardiac Sarcoidosis
Current Medical Imaging Acute Physical Stress Increases Serum Levels of Specific microRNAs
MicroRNA CREG: A Possible Candidate for Both Prevention and Treatment of Proliferative Vascular Disease
Current Molecular Medicine Anticancer Drug Discovery Targeting DNA Hypermethylation
Current Medicinal Chemistry Chilling-Like Attacks Terminated by Slow Pathway Ablation
Current Cardiology Reviews Levosimendan for Heart-Operated Patients: What is the State of the Art?
Recent Patents on Cardiovascular Drug Discovery Atrial Fibrillation Following Cardiac Surgery: Established and Emerging Strategies of Prevention
Recent Patents on Cardiovascular Drug Discovery Possible Exploitation of Non-Neuronal and Non-Chemical Synaptic Signalling Pathways in Epilepsy Therapy
Current Signal Transduction Therapy Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design